Next Article in Journal / Special Issue
Nanobodies that Neutralize HIV
Previous Article in Journal
Why New Vaccines for the Control of Ectoparasite Vectors Have Not Been Registered and Commercialized?
Previous Article in Special Issue
Impact of HIV-1 Diversity on Its Sensitivity to Neutralization
Open AccessReview

Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies

Department of Medical Microbiology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands
Author to whom correspondence should be addressed.
Vaccines 2019, 7(3), 76;
Received: 1 July 2019 / Revised: 23 July 2019 / Accepted: 25 July 2019 / Published: 29 July 2019
(This article belongs to the Special Issue Advances in Antibody-based HIV-1 Vaccine Development)
The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. Many experimental HIV-1 vaccine efforts are therefore aimed at eliciting broadly neutralizing antibodies (bNAbs) that are capable of neutralizing the majority of circulating HIV-1 strains. The envelope glycoprotein (Env) trimer on the viral membrane is the sole target of bNAbs and the key component of vaccination approaches aimed at eliciting bNAbs. Multimeric presentation of Env on nanoparticles often plays a critical role in these strategies. Here, we will discuss the different aspects of nanoparticles in Env vaccination, including recent insights in immunological processes underlying their perceived advantages, the different nanoparticle platforms and the various immunogenicity studies that employed nanoparticles to improve (neutralizing) antibody responses against Env. View Full-Text
Keywords: HIV-1 Env; virus-like particles; liposomes; self-assembling protein nanoparticles HIV-1 Env; virus-like particles; liposomes; self-assembling protein nanoparticles
Show Figures

Figure 1

MDPI and ACS Style

Brinkkemper, M.; Sliepen, K. Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies. Vaccines 2019, 7, 76.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop